Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through …

MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 ...
Yahoo Finance

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after ...

Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo MALVERN, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- via IBN ...
Business Insider

BioVie Announces Update to Parkinson’s Phase 3 Development Program

CARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and ...
Grafa

BioVie advances Phase 3 Parkinson’s drug program

BioVie is preparing a Phase 3 Parkinson’s disease trial for bezisterim after FDA discussions and Phase 2 SUNRISE-PD results.